Please provide your email address to receive an email when new articles are posted on . The updated label shows safety and efficacy in treating moderate to severe atopic dermatitis of the hands or ...

Findings showed 40% of patients treated with dupilumab achieved an IGA score of 0 (clear) or 1 (almost clear) on the hands and feet at week 16, compared with 17% of those who received placebo. The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A total of 40.3% of patients treated with dupilumab ...

More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of ...

Dermatitis is one of the most common skin conditions out there, accounting for things like reactions to new laundry detergents and medically diagnosed cases of eczema. That’s because dermatitis ...

--Regeneron Pharmaceuticals, Inc. and Sanofi today presented positive results from the clinical trial assessing Dupixent ® in adults and adolescents with uncontrolled moderate-to-severe atopic hand ...

“Atopic hand and foot dermatitis can extensively disrupt the lives of patients, given the intense itch and painful skin lesions it causes on essential body areas. In this trial, Dupixent significantly ...